ATE363074T1 - Substrate und screeningverfahren für transportproteine - Google Patents
Substrate und screeningverfahren für transportproteineInfo
- Publication number
- ATE363074T1 ATE363074T1 AT00966735T AT00966735T ATE363074T1 AT E363074 T1 ATE363074 T1 AT E363074T1 AT 00966735 T AT00966735 T AT 00966735T AT 00966735 T AT00966735 T AT 00966735T AT E363074 T1 ATE363074 T1 AT E363074T1
- Authority
- AT
- Austria
- Prior art keywords
- transport proteins
- substrates
- screening methods
- methods
- screening
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5082—Supracellular entities, e.g. tissue, organisms
- G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/06—Esters of carbamic acids
- C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
- C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C271/22—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/08—1,2,5-Oxadiazoles; Hydrogenated 1,2,5-oxadiazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/06—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2
- C07D311/08—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring
- C07D311/16—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring substituted in position 7
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/04—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length on carriers
- C07K1/047—Simultaneous synthesis of different peptide species; Peptide libraries
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
- C12N15/1086—Preparation or screening of expression libraries, e.g. reporter assays
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/531—Production of immunochemical test materials
- G01N33/532—Production of labelled immunochemicals
- G01N33/533—Production of labelled immunochemicals with fluorescent label
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2603/00—Systems containing at least three condensed rings
- C07C2603/02—Ortho- or ortho- and peri-condensed systems
- C07C2603/04—Ortho- or ortho- and peri-condensed systems containing three rings
- C07C2603/06—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members
- C07C2603/10—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members containing five-membered rings
- C07C2603/12—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members containing five-membered rings only one five-membered ring
- C07C2603/18—Fluorenes; Hydrogenated fluorenes
-
- C—CHEMISTRY; METALLURGY
- C40—COMBINATORIAL TECHNOLOGY
- C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
- C40B40/00—Libraries per se, e.g. arrays, mixtures
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pathology (AREA)
- Medicinal Chemistry (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Plant Pathology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Computational Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US15407199P | 1999-09-14 | 1999-09-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE363074T1 true ATE363074T1 (de) | 2007-06-15 |
Family
ID=22549879
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT00966735T ATE363074T1 (de) | 1999-09-14 | 2000-09-14 | Substrate und screeningverfahren für transportproteine |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US7413536B1 (de) |
| EP (1) | EP1212619B1 (de) |
| AT (1) | ATE363074T1 (de) |
| AU (1) | AU7703400A (de) |
| DE (1) | DE60034954D1 (de) |
| WO (1) | WO2001020331A1 (de) |
Families Citing this family (63)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001076531A2 (en) * | 2000-04-07 | 2001-10-18 | University Of Maryland, Baltimore | Bile acid containing prodrugs with enhanced bioavailability |
| US6759398B2 (en) | 2000-08-05 | 2004-07-06 | Smithkline Beecham Corporation | Anti-inflammatory androstane derivative |
| US6858596B2 (en) | 2000-08-05 | 2005-02-22 | Smithkline Beecham Corporation | Formulation containing anti-inflammatory androstane derivative |
| US6858593B2 (en) | 2000-08-05 | 2005-02-22 | Smithkline Beecham Corporation | Anti-inflammatory androstane derivative compositions |
| GB0019172D0 (en) | 2000-08-05 | 2000-09-27 | Glaxo Group Ltd | Novel compounds |
| US6750210B2 (en) | 2000-08-05 | 2004-06-15 | Smithkline Beecham Corporation | Formulation containing novel anti-inflammatory androstane derivative |
| US6777400B2 (en) | 2000-08-05 | 2004-08-17 | Smithkline Beecham Corporation | Anti-inflammatory androstane derivative compositions |
| US6777399B2 (en) | 2000-08-05 | 2004-08-17 | Smithkline Beecham Corporation | Anti-inflammatory androstane derivative compositions |
| US6787532B2 (en) | 2000-08-05 | 2004-09-07 | Smithkline Beecham Corporation | Formulation containing anti-inflammatory androstane derivatives |
| CA2417826A1 (en) | 2000-08-05 | 2002-02-14 | Glaxo Group Limited | 17.beta.-carbothioate 17.alpha.-arylcarbonyloxyloxy androstane derivative as anti-inflammatory agents |
| AU2002230398A1 (en) | 2000-10-06 | 2002-04-29 | Xenoport, Inc. | Bile-acid conjugates for providing sustained systemic concentrations of drugs |
| UA77656C2 (en) | 2001-04-07 | 2007-01-15 | Glaxo Group Ltd | S-fluoromethyl ester of 6-alpha, 9-alpha-difluoro-17-alpha-[(2-furanylcarbonyl)oxy]-11-beta-hydroxy-16- alpha-methyl-3-oxoandrosta-1,4-dien-17-beta-carbothioacid as anti-inflammatory agent |
| AR033290A1 (es) | 2001-04-30 | 2003-12-10 | Glaxo Group Ltd | Derivados antiinflamatorios de androstano |
| US8048917B2 (en) | 2005-04-06 | 2011-11-01 | Xenoport, Inc. | Prodrugs of GABA analogs, compositions and uses thereof |
| EP1412324A4 (de) | 2001-06-11 | 2004-09-29 | Xenoport Inc | Aminosäurekonjugate, die anhaltende systemische konzentrationen von gaba-analoga ergeben |
| JP4342934B2 (ja) | 2001-06-11 | 2009-10-14 | キセノポート インコーポレーティッド | Pept−2輸送体を介した薬剤の投与 |
| US7026166B2 (en) * | 2002-01-22 | 2006-04-11 | Chiron Corporation | Fluorogenic dyes |
| EP1483277A4 (de) | 2002-02-15 | 2007-10-03 | Merckle Gmbh | Konjugate biologisch aktiver verbindungen, verfahren zu deren herstellung und anwendung, formulierung und pharmazeutische anwendungen davon |
| WO2003099338A2 (en) | 2002-05-17 | 2003-12-04 | Xenoport, Inc. | Amino acid conjugates providing for sustained systemic concentrations of gaba analogues |
| FR2840994B1 (fr) * | 2003-01-22 | 2008-07-18 | Commissariat Energie Atomique | Methode de criblage de banques de biomolecules et ses applications |
| FR2840407B1 (fr) * | 2002-05-31 | 2008-07-18 | Commissariat Energie Atomique | Methode de criblage de banques de biomolecules et ses applications |
| AU2003253058A1 (en) | 2002-05-31 | 2003-12-19 | Commissariat A L'energie Atomique | Method of screening groups of radioactive molecules and applications thereof |
| GB2389530B (en) | 2002-06-14 | 2007-01-10 | Cipla Ltd | Pharmaceutical compositions |
| US20040161424A1 (en) * | 2002-10-08 | 2004-08-19 | Xenoport | Human organic solute transporters |
| WO2004041203A2 (en) | 2002-11-04 | 2004-05-21 | Xenoport, Inc. | Gemcitabine prodrugs, pharmaceutical compositions and uses thereof |
| US7704756B2 (en) | 2003-01-21 | 2010-04-27 | Novartis Vaccines And Diagnostics, Inc. | Fluorogenic dyes |
| US7452680B2 (en) | 2004-01-30 | 2008-11-18 | Xenoport, Inc. | MCT1 transporters expressed in blood brain barrier cells |
| US7910593B2 (en) * | 2004-04-09 | 2011-03-22 | Chugai Seiyaku Kabushiki Kaisha | Water-soluble prodrugs |
| CA2571407A1 (en) | 2004-07-12 | 2006-02-16 | Xenoport, Inc. | Amino acid derived prodrugs of propofol, compositions and uses thereof |
| US7241807B2 (en) | 2004-07-12 | 2007-07-10 | Xenoport, Inc. | Prodrugs of propofol, compositions and uses thereof |
| TW200744603A (en) | 2005-08-22 | 2007-12-16 | Chugai Pharmaceutical Co Ltd | Novel anticancer concomitant drug |
| JP2009510198A (ja) | 2005-09-26 | 2009-03-12 | インヴィトロジェン コーポレーション | 紫色レーザー励起性色素及びその使用方法 |
| WO2007087993A1 (en) * | 2006-01-31 | 2007-08-09 | Sanofi-Aventis | Method for the determination of the activity of the organic cation transporter |
| EP1991702A4 (de) * | 2006-02-17 | 2009-04-22 | Univ Leland Stanford Junior | Sequenzielle reportergen-lumineszenz (srl)-verfahren und zusammensetzung zu ihrer ausführung |
| DK2011880T3 (da) * | 2006-04-13 | 2012-11-26 | Chugai Pharmaceutical Co Ltd | Taurin transportergen |
| US8058260B2 (en) | 2006-05-22 | 2011-11-15 | Xenoport, Inc. | 2′-C-methyl-ribofuranosyl cytidine prodrugs, pharmaceutical compositions and uses thereof |
| WO2008073856A2 (en) * | 2006-12-08 | 2008-06-19 | Massachusetts Institute Of Technology | Delivery of nanoparticles and/or agents to cells |
| JP5635260B2 (ja) | 2007-03-15 | 2014-12-03 | 中外製薬株式会社 | ポリペプチドの製造方法 |
| CA2695849C (en) | 2007-08-07 | 2018-10-16 | Chugai Seiyaku Kabushiki Kaisha | Method of producing heterogeneous proteins |
| RU2486245C2 (ru) | 2007-10-15 | 2013-06-27 | Чугаи Сейяку Кабусики Кайся | Способ получения клетки, способной продуцировать гетеропротеины с высоким выходом |
| AU2008314973C1 (en) | 2007-10-24 | 2014-05-08 | Chugai Seiyaku Kabushiki Kaisha | A cell for use in production of heteroproteins and production method using the same |
| US20120058937A9 (en) * | 2008-04-15 | 2012-03-08 | Tsrl, Inc. | Prodrugs of Neuraminidase Inhibitors |
| WO2010094027A1 (en) * | 2009-02-13 | 2010-08-19 | X-Body, Inc. | Identification of nucleic acid delivery vehicles using dna display |
| SG173627A1 (en) | 2009-02-13 | 2011-09-29 | Chem Inc X | Methods of creating and screening dna-encoded libraries |
| US8741601B2 (en) | 2009-04-22 | 2014-06-03 | Chugai Seiyaku Kabushiki Kaisha | Method for producing a cell capable of high-yield production of heteroproteins |
| US8367842B2 (en) * | 2009-07-16 | 2013-02-05 | Beckman Coulter, Inc. | Fluorescent dyes and uses thereof |
| JP5561692B2 (ja) * | 2010-03-09 | 2014-07-30 | 国立大学法人群馬大学 | 新規蛍光化合物およびそれを用いた細胞内コレステロールの検出方法 |
| EP4137137A1 (de) | 2010-05-26 | 2023-02-22 | Satiogen Pharmaceuticals, Inc. | Gallensäurerecyclinghemmer und satiogene zur behandlung von diabetes, adipositas und entzündlichen magen-darm-erkrankungen |
| US8399262B2 (en) | 2011-03-23 | 2013-03-19 | Darrel A. Mazzari | Biosensor |
| DK2748357T3 (en) | 2011-09-07 | 2018-07-16 | X Chem Inc | Methods for labeling DNA-encoded libraries |
| EA038594B1 (ru) | 2011-10-28 | 2021-09-21 | Шайр Хьюман Дженетик Терапис, Инк. | Ингибиторы рециркуляции желчных кислот для лечения гиперхолемии и холестатического заболевания печени |
| JP6217938B2 (ja) | 2011-10-28 | 2017-10-25 | ルメナ ファーマシューティカルズ エルエルシー | 小児の胆汁うっ滞性肝疾患の処置のための胆汁酸再循環阻害剤 |
| KR102146721B1 (ko) | 2012-07-13 | 2020-08-21 | 엑스-켐, 인크. | 폴리머라제에 의해 판독가능하지 않은 코딩 올리고뉴클레오티드 연결을 갖는 dna-코딩된 라이브러리 |
| KR20160002773A (ko) | 2013-03-15 | 2016-01-08 | 루메나 파마수티컬즈, 인코포레이티드 | 원발성 담관염 및 염증성 장 질환 치료용 담즙산 재순환 억제제 |
| AU2014229050A1 (en) | 2013-03-15 | 2015-10-22 | Lumena Pharmaceuticals Llc | Bile acid recycling inhibitors for treatment of Barrett's esophagus and gastroesophageal reflux disease |
| US9988624B2 (en) | 2015-12-07 | 2018-06-05 | Zymergen Inc. | Microbial strain improvement by a HTP genomic engineering platform |
| JP6821598B2 (ja) | 2015-12-07 | 2021-01-27 | ザイマージェン インコーポレイテッド | Corynebacterium glutamicum由来のプロモーター |
| EP3478833A4 (de) | 2016-06-30 | 2019-10-02 | Zymergen, Inc. | Verfahren zum erzeugen einer bakteriellen hämoglobin-bibliothek und deren verwendung |
| US10544411B2 (en) | 2016-06-30 | 2020-01-28 | Zymergen Inc. | Methods for generating a glucose permease library and uses thereof |
| GB2552460A (en) * | 2016-07-11 | 2018-01-31 | Evox Therapeutics Ltd | CPP-Mediated EV Loading |
| EP4424363B1 (de) | 2019-02-12 | 2026-04-29 | Mirum Pharmaceuticals, Inc. | Verfahren zur wachstumssteigerung bei pädiatrischen patienten mit cholestatischer lebererkrankung |
| US20230146782A1 (en) * | 2019-08-06 | 2023-05-11 | Du Jessica Xinyun | Deoxycholic acid compounds, pharmaceutical compositions and uses thereof |
| US11951186B2 (en) | 2019-10-25 | 2024-04-09 | Willow Laboratories, Inc. | Indicator compounds, devices comprising indicator compounds, and methods of making and using the same |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| US5569678A (en) | 1989-07-31 | 1996-10-29 | Massachusetts Institute Of Technology | Control of wound scar production |
| DE3930696A1 (de) | 1989-09-14 | 1991-03-28 | Hoechst Ag | Gallensaeurederivate, verfahren zu ihrer herstellung, verwendung als arzneimittel |
| US5866123A (en) * | 1990-04-13 | 1999-02-02 | Research Development Foundation | Gene encoding cationic amino acid transporter protein |
| US5236902A (en) * | 1990-11-26 | 1993-08-17 | The Governors Of The University Of Alberta | Method and probes for detecting nucleoside transporter and method for producing the probes |
| US5580775A (en) | 1992-05-01 | 1996-12-03 | Emory University | High affinity, brain-specific nucleic acids encoding a L-proline transporter, and vectors, and host cells comprising the same |
| US5607691A (en) | 1992-06-12 | 1997-03-04 | Affymax Technologies N.V. | Compositions and methods for enhanced drug delivery |
| DE4222315A1 (de) * | 1992-07-05 | 1994-01-13 | Inst Genbiologische Forschung | DNA-Sequenzen für Aminosäuretransporter, Plasmide, Bakterien, Hefen und Pflanzen enthaltend einen Transporter |
| DE614989T1 (de) | 1993-02-17 | 1995-09-28 | Morphosys Proteinoptimierung | Verfahren für in vivo Selektion von Ligandenbindende Proteine. |
| US5658782A (en) * | 1993-10-20 | 1997-08-19 | State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education On Behalf Of The Oregon Health Sciences University A Non-Profit Organization | Amino acid transporters and uses |
| DE4343527A1 (de) * | 1993-12-16 | 1995-06-22 | Schering Ag | Verfahren zur Identifizierung von Stoffen mit potentieller herbizider oder wachstumsregulatorischer Wirkung mittels pflanzlicher Transporterproteine, Verwendung der Transporterproteine sowie Substanzen mit herbizider und wachstumsregulatorischer Wirkung |
| US5589358A (en) * | 1993-12-29 | 1996-12-31 | Univ Wake Forest | Ileal bile acid transporter compositions and methods |
| US5849525A (en) | 1994-03-09 | 1998-12-15 | Brigham And Women's Hospital, Inc. | Compositions corresponding to a proton-coupled peptide transporter and methods of making and using same |
| US5750788A (en) * | 1994-11-12 | 1998-05-12 | Basf Aktiengesellschaft | Preparation of amines from compounds having at least 3 cyano groups |
| US5824485A (en) * | 1995-04-24 | 1998-10-20 | Chromaxome Corporation | Methods for generating and screening novel metabolic pathways |
| AU693723B2 (en) | 1995-09-11 | 1998-07-02 | La Jolla Cancer Research Foundation | Molecules that home to a selected organ or tissue in vivo and methods of identifying same |
| NZ322175A (en) | 1995-11-10 | 1999-02-25 | Elan Corp Plc | Peptides which enhance transport across tissues and methods of identifying the same |
| US5780264A (en) | 1996-06-06 | 1998-07-14 | The President And Fellows Of Harvard College | Iron transport protein |
| EP0923603A1 (de) * | 1996-07-16 | 1999-06-23 | Novo Nordisk A/S | Oligopeptid-transporter |
| US6361938B1 (en) | 1996-11-08 | 2002-03-26 | Elan Corporation, Plc | Peptides which enhance transport across tissues and methods of identifying and using the same |
| DE69839501D1 (de) * | 1997-02-27 | 2008-06-26 | Cellomics Inc | System für Screening biologischer Zellen |
| US6057098A (en) | 1997-04-04 | 2000-05-02 | Biosite Diagnostics, Inc. | Polyvalent display libraries |
| CA2290756A1 (en) | 1997-05-15 | 1998-11-19 | Cytogen Corporation | Random peptides that bind to gastro-intestinal tract (git) transport receptors and related methods |
| JP4044728B2 (ja) | 1997-07-15 | 2008-02-06 | メディクエスト セラピューティックス インク | 治療および診断薬剤としての新規なポリアミンアナログ |
-
2000
- 2000-09-14 AU AU77034/00A patent/AU7703400A/en not_active Abandoned
- 2000-09-14 WO PCT/US2000/025439 patent/WO2001020331A1/en not_active Ceased
- 2000-09-14 DE DE60034954T patent/DE60034954D1/de not_active Expired - Lifetime
- 2000-09-14 US US09/661,927 patent/US7413536B1/en not_active Expired - Fee Related
- 2000-09-14 EP EP00966735A patent/EP1212619B1/de not_active Expired - Lifetime
- 2000-09-14 AT AT00966735T patent/ATE363074T1/de not_active IP Right Cessation
-
2008
- 2008-07-14 US US12/172,801 patent/US20090221442A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP1212619A4 (de) | 2004-12-08 |
| EP1212619A1 (de) | 2002-06-12 |
| US20090221442A1 (en) | 2009-09-03 |
| DE60034954D1 (de) | 2007-07-05 |
| WO2001020331A9 (en) | 2002-10-03 |
| WO2001020331A1 (en) | 2001-03-22 |
| US7413536B1 (en) | 2008-08-19 |
| EP1212619B1 (de) | 2007-05-23 |
| AU7703400A (en) | 2001-04-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60034954D1 (de) | Substrate und screeningverfahren für transportproteine | |
| NO20043245L (no) | Bindingsproteiner som biosensorer | |
| NO20043259L (no) | Bindingsproteiner som biosensorer | |
| EP1687283A4 (de) | Für die bestimmung von fk506 geeignetes verfahren und zusammensetzung | |
| ATE295347T1 (de) | Stoffe und zusammensetzungen für die verabreichung aktiver substanzen | |
| DE60137203D1 (de) | Poröse ferro- oder ferrimagnetische glasteilchen für molekültrennung | |
| DK1053256T3 (da) | Antistoffer mod Dødsreceptor 4 (DR4) og anvendelser deraf | |
| DE60005787D1 (de) | Wasserlösliche rhodaminfarbstoffe und ihre konjugate | |
| NO20043257L (no) | Innkapslede bindingsproteiner som biosensorer | |
| ATE233762T1 (de) | Bicyclische polyamiosaure metallkomplexe, verfahren zu ihrer herstellung und ihre verwendung für medizinische bilderzeugung | |
| DE69739856D1 (de) | Agonisten für den rezeptor des hepatozyten-wachstumsfaktors und deren anwendungen | |
| ATE294164T1 (de) | Fluoreszenzfarbstoffe zum festphasen- und flüssigphasen-screening | |
| ATE352784T1 (de) | Verfahren zum screenen für gpr40-liganden | |
| ITRM980303A0 (it) | Composizione contenente radioisotopi immobilizzati su particelle solide utile in particolare per la biancheria clinica in patologie | |
| TR200101663T2 (tr) | Pro-kollajen c-proteinaz inhibitörleri | |
| DE59806371D1 (de) | Kontrastmittel für das infarkt- und nekroseimaging | |
| DE69912839D1 (de) | Nrihydroxstilbene enthaltende produkte und deren derivate und verfahren zur deren herstellung und ihre verwendung | |
| GB0208989D0 (en) | Methods for measuring enzyme activity | |
| WO1999050459A3 (en) | High throughput in vitro screening assays for transcription modulators | |
| DK1049721T3 (da) | Syntetiske polysaccharider, fremgangsmåde til fremstilling heraf og farmaceutiske præparater indeholdende disse | |
| MXPA03001536A (es) | (aminoalcoxibenzoil) benzofuranos o benzotiofenos, metodo para preparar los mismo y composiciones que los contienen. | |
| MXPA03011898A (es) | Ensayo de seleccion in vitro para ?- secretasa. | |
| WO2001008707A3 (de) | Konjugate und verfahren zu deren herstellung sowie deren verwendung zum transport von molekülen über biologische membranen | |
| ATE252574T1 (de) | Benzofuran-2-ones als färbemittel für organische materialien | |
| ATE256120T1 (de) | Reagentien für cyp2d fluoreszenztest |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |